SCHEMBL396223

SCHEMBL396223

Cc1cn(-c2cc(C(=O)Nc3cccc(Nc4ccc5c(c4)NC(=O)C5=Cc4[nH]c(C)c(C(=O)NCC(O)CO)c4C)c3)cc(C(F)(F)F)c2)cn1

nearest known ligand 0.68

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ NTRK1 P04629 8/20 0.68
▸ NTRK2 Q16620 8/20 0.68
▸ RAF1 P04049 4/20 0.68
▸ AURKA O14965 1/20 0.68
▸ SRC P12931 1/20 0.68
▸ NTRK3 Q16288 1/20 0.47
▸ BRAF P15056 3/20 0.46
▸ CSF1R P07333 3/20 0.46
▸ AURKB Q96GD4 2/20 0.43
▸ KIT P10721 1/20 0.43
▸ FLT4 P35916 1/20 0.43
▸ KDR P35968 1/20 0.43
▸ FLT3 P36888 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10091921 1.00 NTRK1 (0.68) NTRK1NTRK2RAF1AURKASRC
SCHEMBL396704 0.90 NTRK1 (0.76) NTRK1NTRK2RAF1AURKASRC
SCHEMBL396703 0.90 NTRK1 (0.76) NTRK1NTRK2RAF1AURKASRC
SCHEMBL396894 0.89 NTRK2 (0.69) NTRK1NTRK2RAF1AURKASRC
SCHEMBL10091918 0.89 NTRK2 (0.69) NTRK1NTRK2RAF1AURKASRC
SCHEMBL396224 0.87 NTRK1 (0.65) NTRK1NTRK2RAF1AURKASRC
SCHEMBL4124627 0.86 NTRK1 (0.71) NTRK1NTRK2RAF1AURKASRC
SCHEMBL4002779 0.86 NTRK1 (0.71) NTRK1NTRK2RAF1AURKASRC
SCHEMBL396340 0.86 NTRK2 (0.69) NTRK1NTRK2RAF1AURKASRC
SCHEMBL10091887 0.86 NTRK2 (0.69) NTRK1NTRK2RAF1AURKASRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101608-B2 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems IRM LLC, a Delware Limited Corporation (BM) 2012-01-24 — — US claimed
US-8101608-B2 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems IRM LLC, a Delware Limited Corporation (BM) 2012-01-24 — — US disclosed
Send feedback